Singer FR, Bone HG III, Hosking DJ, Lyles KW, Murad MH, Reid IR, Siris ES (2014) Paget’s disease of bone: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99:4408–4422

Article  CAS  PubMed  Google Scholar 

Ralston SH, Corral-Gudino L, Cooper C, Francis RM, Fraser WD, Gennari L, Guañabens N, Javaid MK, Layfield R, O’Neill TW, Russell RGG, Stone MD, Simpson K, Wilkinson D, Wills R, Zillikens MC, Tuck SP (2019) Diagnosis and management of Paget’s disease of bone in adults: a clinical guideline. J Bone Miner Res 34:579–604

Article  PubMed  Google Scholar 

Cundy T (2018) Paget’s disease of bone. Metabolism 80:5–14

Article  CAS  PubMed  Google Scholar 

Cook SJ, Wall C (2021) Paget’s disease of bone: a clinical update. Aust J Gen Pract 50:23–29

Article  PubMed  Google Scholar 

Hashimoto J, Ohno I, Nakatsuka K, Yoshimura N, Takata S, Zamma M, Yabe H, Abe S, Terada M, Yoh K, Fukunaga M, Cooper C, Morii H, Yoshikawa H (2006) Prevalence and clinical features of Paget’s disease of bone in Japan. J Bone Miner Metab 24:186–190

Article  PubMed  Google Scholar 

Takata S, Hashimoto J, Nakatsuka K, Yoshimura N, Yoh K, Ohno I, Yabe H, Abe S, Fukunaga M, Terada M, Zamma M, Ralston SH, Morii H, Yoshikawa H (2006) Guidelines for diagnosis and management of Paget’s disease of bone in Japan. J Bone Miner Metab 24:359–367

Article  PubMed  Google Scholar 

Corral-Gudino L, Tan AJ, Del Pino-Montes J, Ralston SH (2017) Bisphosphonates for Paget’s disease of bone in adults. Cochrane Database Syst Rev 12:cd004956

PubMed  Google Scholar 

Langston AL, Ralston SH (2004) Management of Paget’s disease of bone. Rheumatology (Oxford) 43:955–959

Article  CAS  PubMed  Google Scholar 

Yoh K, Takata S, Yoshimura N, Hashimoto J (2010) Efficacy, tolerability, and safety of risedronate in Japanese patients with Paget’s disease of bone. J Bone Miner Metab 28:468–476

Article  CAS  PubMed  Google Scholar 

Reid IR, Lyles K, Su G, Brown JP, Walsh JP, del Pino-Montes J, Miller PD, Fraser WD, Cafoncelli S, Bucci-Rechtweg C, Hosking DJ (2011) A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years. J Bone Miner Res 26:2261–2270

Article  CAS  PubMed  Google Scholar 

Woitge HW, Oberwittler H, Heichel S, Grauer A, Ziegler R, Seibel MJ (2000) Short- and long-term effects of ibandronate treatment on bone turnover in Paget disease of bone. Clin Chem 46:684–690

Article  CAS  PubMed  Google Scholar 

Reid IR, Brown JP, Levitt N, Román Ivorra JA, Bachiller-Corral J, Ross IL, Su G, Antunez-Flores O, Aftring RP (2013) Re-treatment of relapsed Paget’s disease of bone with zoledronic acid: results from an open-label study. Bonekey Rep 2:442

Article  PubMed  PubMed Central  Google Scholar 

Barale M, Sigrist S, Bioletto F, Maiorino F, Ghigo E, Mazzetti R, Procopio M (2021) Long-term efficacy of intensive zoledronate therapy and predictors of retreatment in Paget’s disease of bone. Calcif Tissue Int 109:383–392

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eekhoff ME, Zwinderman AH, Haverkort DM, Cremers SC, Hamdy NA, Papapoulos SE (2003) Determinants of induction and duration of remission of Paget’s disease of bone after bisphosphonate (olpadronate) therapy. Bone 33:831–838

Article  CAS  PubMed  Google Scholar 

Ohara M, Imanishi Y, Nagata Y, Ishii A, Kobayashi I, Mori K, Ito M, Miki T, Nishizawa Y, Inaba M (2015) Clinical efficacy of oral risedronate therapy in Japanese patients with Paget’s disease of bone. J Bone Miner Metab 33:584–590

Article  CAS  PubMed  Google Scholar 

Papapoulos SE, Eekhoff EM, Zwinderman AH (2006) Acquired resistance to bisphosphonates in Paget’s disease of bone. J Bone Miner Res 21:P88-91

Article  CAS  PubMed  Google Scholar 

Vittinghoff E, McCulloch CE (2007) Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol 165:710–718

Article  PubMed  Google Scholar 

Langston AL, Campbell MK, Fraser WD, MacLennan GS, Selby PL, Ralston SH (2010) Randomized trial of intensive bisphosphonate treatment versus symptomatic management in Paget’s disease of bone. J Bone Miner Res 25:20–31

Article  CAS  PubMed  Google Scholar 

Siris ES, Chines AA, Altman RD, Brown JP, Johnston CC Jr, Lang R, McClung MR, Mallette LE, Miller PD, Ryan WG, Singer FR, Tucci JR, Eusebio RA, Bekker PJ (1998) Risedronate in the treatment of Paget’s disease of bone: an open label, multicenter study. J Bone Miner Res 13:1032–1038

Article  CAS  PubMed  Google Scholar 

Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y, Mesenbrink P, Su G, Pak J, Zelenakas K, Luchi M, Richardson P, Hosking D (2005) Comparison of a single infusion of zoledronic acid with risedronate for Paget’s disease. N Engl J Med 353:898–908

Article  CAS  PubMed  Google Scholar 

Hosking DJ, Eusebio RA, Chines AA (1998) Paget’s disease of bone: reduction of disease activity with oral risedronate. Bone 22:51–55

Article  CAS  PubMed  Google Scholar 

Fleisch H (2001) Development of bisphosphonates. Breast Cancer Res 4:30

Article  PubMed  PubMed Central  Google Scholar 

Ohta H, Nishikawa M, Kamisaki T, Umemura T, Itoh M, Uchida S (2012) Safety and efficacy of risedronate 17.5 mg tablets in prospective observation study including male patients with osteoporosis—48 weeks treatment by risedronate 17.5 mg tablets under good post-marketing study practice. Osteoporos Jpn 20:697–707

Google Scholar 

Papapetrou PD (2009) Bisphosphonate-associated adverse events. Hormones (Athens) 8:96–110

Article  PubMed  Google Scholar 

Soen S, Arai Y, Matsuda S, Emori K, Ikezaki T, Osawa M (2020) A 3-year postmarketing study on the safety and effectiveness of once-monthly risedronate in Japanese patients with osteoporosis. Osteoporos Sarcopenia 6:191–198

Article  PubMed  PubMed Central  Google Scholar